216 related articles for article (PubMed ID: 33919658)
1. Initial Transarterial Chemoembolization (TACE) Using HepaSpheres 20-40 µm and Subsequent Lipiodol TACE in Patients with Hepatocellular Carcinoma > 5 cm.
Cho SM; Chu HH; Kim JW; Kim JH; Gwon DI
Life (Basel); 2021 Apr; 11(4):. PubMed ID: 33919658
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the Treatment Response of Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma.
Adel H; Shazlee MK; Qamar S; Hyder SMS; Razaque A
Cureus; 2023 Jul; 15(7):e41701. PubMed ID: 37575777
[TBL] [Abstract][Full Text] [Related]
3. Lipiodol combined with drug-eluting beads versus drug-eluting beads alone for transarterial chemoembolization of hepatocellular carcinoma: a multicenter study.
Ji K; Shi Y; Liang Z; Zhang C; Jing L; Xu T; Cao S; Zhou G; Cao Y; Niu J; Zhu J; Ai J; Li Z; Chen F
Acad Radiol; 2024 Jun; ():. PubMed ID: 38866689
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Treatment Response and Survival Profiles Between Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients: A Prospective Cohort Study.
Wen P; Chen SD; Wang JR; Zeng YH
Oncol Res; 2019 May; 27(5):583-592. PubMed ID: 31053181
[TBL] [Abstract][Full Text] [Related]
5. Survival and Outcome in Patients Receiving Drug-Eluting Beads Transarterial Chemoembolization for Large Hepatocellular Carcinoma (>5 cm).
Mukund A; Bhardwaj K; Choudhury A; Sarin SK
J Clin Exp Hepatol; 2021; 11(6):674-681. PubMed ID: 34866846
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Transarterial Chemoembolization Protocol with Drug-Eluting Beads in Combination with Lipiodol for Hepatocellular Carcinoma: A Single-Center Controlled Study.
Dong X; Wang Y; Hao J; Chen L; Sun T; Zhang W; Sun B; Zhu L; Guo Y; Zheng C
J Oncol; 2022; 2022():1090313. PubMed ID: 36568640
[TBL] [Abstract][Full Text] [Related]
7. Duration of response after DEB-TACE compared to lipiodol-TACE in HCC-naïve patients: a propensity score matching analysis.
Bargellini I; Lorenzoni V; Lorenzoni G; Scalise P; Andreozzi G; Bozzi E; Giorgi L; Cervelli R; Scandiffio R; Perrone O; Meccia DV; Boccuzzi A; Daviddi F; Cicorelli A; Lunardi A; Crocetti L; Turchetti G; Cioni R
Eur Radiol; 2021 Oct; 31(10):7512-7522. PubMed ID: 33871708
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of drug-eluting bead transarterial chemoembolization versus conventional transarterial chemoembolization for small hepatocellular carcinoma in Child-Pugh class A patients.
Lee IJ; Lee JH; Lee YB; Kim YJ; Yoon JH; Yin YH; Lee M; Hur S; Kim HC; Jae HJ; Chung JW
Ther Adv Med Oncol; 2019; 11():1758835919866072. PubMed ID: 31447948
[TBL] [Abstract][Full Text] [Related]
9. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
[TBL] [Abstract][Full Text] [Related]
10. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma.
Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY
Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378
[TBL] [Abstract][Full Text] [Related]
11. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
[TBL] [Abstract][Full Text] [Related]
12. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P
Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338
[No Abstract] [Full Text] [Related]
13. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
[TBL] [Abstract][Full Text] [Related]
14. Transarterial chemoembolization using drug-eluting bead compared with radiofrequency ablation for treatment of single small hepatocellular carcinoma: a pilot non-randomized trial.
Kim TH; Kim NH; Kim JD; Kim YN; Kim YJ; Kim EJ; Yoo KD; Ryu CH; Song HH; Kim H
J Liver Cancer; 2021 Sep; 21(2):146-154. PubMed ID: 37383084
[TBL] [Abstract][Full Text] [Related]
15. Transarterial chemoembolization with Doxorubicin-eluting microspheres for inoperable hepatocellular carcinoma.
Kalva SP; Iqbal SI; Yeddula K; Blaszkowsky LS; Akbar A; Wicky S; Zhu AX
Gastrointest Cancer Res; 2011 Jan; 4(1):2-8. PubMed ID: 21464864
[TBL] [Abstract][Full Text] [Related]
16. Comparison of initial tumor responses to transarterial bland embolization and drug-eluting beads-transarterial chemoembolization in the management of hepatocellular carcinoma: a propensity-score matching analysis.
Guo J; Wang W; Zhang Y; Xu L; Kong J
J Gastrointest Oncol; 2021 Aug; 12(4):1838-1850. PubMed ID: 34532132
[TBL] [Abstract][Full Text] [Related]
17. Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study.
Lee S; Kim KM; Lee SJ; Lee KH; Lee DY; Kim MD; Kim DY; Kim SU; Won JY
Acta Radiol; 2017 Feb; 58(2):131-139. PubMed ID: 27217418
[TBL] [Abstract][Full Text] [Related]
18. Delayed intratumoral hemorrhage after drug-eluting bead transarterial chemoembolization for hepatocellular carcinoma.
Shiozawa K; Watanabe M; Ikehara T; Ogino Y; Umakoshi T; Matsukiyo Y; Kogame M; Matsui T; Kikuchi Y; Igarashi Y; Sumino Y
Case Rep Oncol; 2014 Sep; 7(3):739-45. PubMed ID: 25520649
[TBL] [Abstract][Full Text] [Related]
19. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
Wu B; Zhou J; Ling G; Zhu D; Long Q
World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
[TBL] [Abstract][Full Text] [Related]
20. Drug-Eluting Beads versus Lipiodol Transarterial Chemoembolization for the Treatment of Hypovascular Hepatocellular Carcinoma: A Single-Center Retrospective Study.
Shi Q; Chen D; Zhou C; Liu J; Huang S; Yang C; Xiong B
Cancer Manag Res; 2020; 12():5461-5468. PubMed ID: 32753963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
